Shares of DexCom, Inc. (NASDAQ:DXCM – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the eighteen brokerages that are presently covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $112.25.
Several brokerages have issued reports on DXCM. Oppenheimer lowered their target price on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, July 26th. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Barclays cut their price objective on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a report on Monday, July 29th. Wells Fargo & Company lowered their target price on DexCom from $145.00 to $80.00 and set an “overweight” rating on the stock in a report on Friday, July 26th. Finally, JPMorgan Chase & Co. cut DexCom from an “overweight” rating to a “neutral” rating and cut their price target for the company from $145.00 to $75.00 in a report on Friday, July 26th.
Check Out Our Latest Stock Analysis on DXCM
Insider Buying and Selling
Institutional Investors Weigh In On DexCom
A number of hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in shares of DexCom by 0.3% during the first quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company’s stock worth $6,186,539,000 after acquiring an additional 136,282 shares during the period. Capital Research Global Investors increased its holdings in DexCom by 21.4% during the 4th quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock worth $1,898,085,000 after purchasing an additional 2,695,296 shares during the period. Capital World Investors raised its position in DexCom by 130.7% in the 4th quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock valued at $1,151,392,000 after purchasing an additional 5,256,092 shares in the last quarter. Blair William & Co. IL raised its position in DexCom by 1.4% in the 1st quarter. Blair William & Co. IL now owns 4,532,687 shares of the medical device company’s stock valued at $628,684,000 after purchasing an additional 64,683 shares in the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of DexCom by 1.7% in the 2nd quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock valued at $339,352,000 after buying an additional 49,076 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.
DexCom Stock Up 3.7 %
DXCM stock opened at $68.11 on Monday. DexCom has a 52 week low of $62.34 and a 52 week high of $142.00. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. The firm has a 50-day simple moving average of $70.19 and a 200-day simple moving average of $104.75. The stock has a market capitalization of $27.09 billion, a P/E ratio of 43.94, a P/E/G ratio of 2.16 and a beta of 1.18.
DexCom (NASDAQ:DXCM – Get Free Report) last posted its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.39 by $0.04. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. DexCom’s quarterly revenue was up 15.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.34 EPS. Equities analysts forecast that DexCom will post 1.69 earnings per share for the current fiscal year.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Further Reading
- Five stocks we like better than DexCom
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- 3 Key Stocks to Ride China’s Stimulus-Driven Growth
- What Investors Need to Know About Upcoming IPOs
- 3 Dividend Growth Stocks Set to Supercharge Your Portfolio
- Russell 2000 Index, How Investors Use it For Profitable Trading
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.